๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A probe for intracerebral aromatic amino-acid decarboxylase activity: Distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain

โœ Scribed by Dr. Claude Nahmias; Lindi Wahl; Raman Chirakal; Gunter Firnau; E. Stephen Garnett


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
600 KB
Volume
10
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Positron tomography, using ['8F]6-fluoro-~-dopa as a tracer, has been used for the study of Parkinson's disease. Unfortunately, the analysis of data obtained with this agent is bedeviled because it readily forms labeled methylated metabolites that enter the brain. We have evaluated ['sF16-fluoro-L-m-tyrosine (FmT) as an alternative tracer to study intracerebral dopamine metabolism with positron tomography. Imaging studies in humans showed specific accumulation of this tracer in the dopamine-rich striatal regions. Reduced striatal uptake of the tracer was demonstrated in a patient suffering from Parkinson's disease. Increased retention of the tracer was demonstrated in a subject pretreated with the peripheral decarboxylase inhibitor carbidopa. Analysis of plasma samples for labeled metabolites of FmT revealed no methylated metabolites. Results of compartmental analysis showed that a twocompartment three rate constant model described adequately the time course of radioactivity in the striatum after an injection of FmT. The FmT decarboxylation rate constant (k2J was found to be 0.0108 min-'. Because the peripheral metabolism of FmT is simpler than that of ['8F]6-fluoro-~-dopa, we propose FmT as a superior agent with which to study intracerebral dopamine metabolism in health and disease in humans.


๐Ÿ“œ SIMILAR VOLUMES


Localization of trapping of 6-[18F]fluor
โœ W. Douglas Brown; Onofre T. DeJesus; Robert W. Pyzalski; Lisamarie Malischke; An ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 488 KB

The purpose of this study was to address four major questions regarding 6-FMT, a noncatecholic PET tracer for AAAD: 1) Where is the specific uptake of 6-FMT? 2) Why does it accumulate where and to the degree that it does? 3) How does its uptake differ from that of fluoroDOPA globally? and 4) Does it